It is clear that this is a major challenge that the medical community has yet to adequately tackle.
The World Health Organization (WHO) and the World Health Organisation-United Nations Conference on Trade and Development (UNCTAD) are set to discuss the global situation with representatives of the medical profession and the pharmaceutical industry at an emergency meeting in New York on Wednesday.
It is expected that they will agree that vaccines should be made available to all countries in line with international standards.
However, many experts are warning that there is a problem with the quality of the vaccines being produced and that some are not getting the dose they need.
Vaccines that were not ready for public consumption, such as the first generation of COVID-19 vaccines, are already out there and have shown some positive results.
For instance, the first-generation vaccines, called LAIV and LAIV-19, were widely available in the US before the outbreak.
They have shown promising results in reducing the virus in the lungs of people with respiratory diseases, such an influenza-like illness.
A second generation of vaccines, the CELI vaccines, have been made available in India and other countries in Asia.
This means that the US has a much more robust vaccine against COVID than India, and many other countries.
Despite the success of the first vaccines, there are concerns that many of the doses of vaccines produced are not up to par with the vaccine doses needed to control COVID.
We must ensure that we are getting enough vaccine doses for every country in line, said Dr Richard Wimmer, an expert in infectious diseases and epidemiology at University College London.
“We must not allow our country to get caught in the crossfire of the vaccine debate,” he added.
In terms of the global fight against COVS, there has been a rapid decline in the number of cases in the past few years.
On Tuesday, WHO reported that COVID deaths were down to 5,000, and the number with a hospitalisation or death was down to 1.2 million.